EndoDNA Company Profile

Background

Overview

EndoDNA, officially known as Endocanna Health, Inc., is a biotechnology research company specializing in precision health through AI-driven genomic analysis. Founded in 2017 and headquartered in Burbank, California, the company focuses on personalizing health insights by translating complex genomic data into actionable recommendations and treatment pathways. Their flagship platform, MyDNA.live, serves as a comprehensive provider portal that enhances patient evaluation processes.

Mission and Vision

EndoDNA's mission is to bridge the gap between complex genomics and patient wellness by providing personalized health insights through DNA analysis. Their vision is to empower healthcare providers and individuals with precise, actionable genetic information to optimize health and wellness outcomes.

Primary Area of Focus

The company's primary focus is on precision medicine, particularly in the realm of cannabinoid therapeutics. By analyzing genetic markers related to the endocannabinoid system, EndoDNA aims to tailor cannabinoid and terpene profiles to individual genetic makeups, enhancing therapeutic efficacy and safety.

Industry Significance

EndoDNA holds a significant position in the biotechnology and health diagnostics industry by pioneering personalized cannabinoid therapy. Their integration of AI and genomic data analysis sets them apart in the precision medicine landscape, offering innovative solutions for personalized healthcare.

Key Strategic Focus

Core Objectives

• Personalized Health Insights: Deliver tailored health recommendations based on individual genetic profiles.

• Precision Cannabinoid Therapy: Optimize cannabinoid and terpene formulations to align with genetic predispositions.

• AI Integration: Utilize artificial intelligence to enhance the interpretation of genomic data and improve therapeutic outcomes.

Specific Areas of Specialization

• Genomic Analysis: Conduct comprehensive DNA testing to identify genetic variants affecting health and wellness.

• Cannabinoid Research: Focus on the endocannabinoid system to develop personalized cannabinoid therapies.

• AI-Driven Solutions: Implement machine learning algorithms to predict treatment efficacy and tailor wellness plans.

Key Technologies Utilized

• MyDNA.live Platform: A secure, HIPAA-compliant portal providing personalized health reports and recommendations.

• Endo·Decoded Report: A detailed analysis of genetic variants related to cannabinoid metabolism and response.

• Endo·Aligned Formulations: Product recommendations tailored to individual genetic profiles.

Primary Markets Targeted

• Healthcare Providers: Clinicians seeking personalized treatment plans for patients.

• Consumers: Individuals interested in personalized health and wellness solutions.

• Research Institutions: Organizations conducting studies on genetics and cannabinoid therapies.

Financials and Funding

Funding History

EndoDNA has raised over $3 million in funding since its inception.

Recent Funding Rounds

Specific details regarding recent funding rounds are not publicly disclosed.

Notable Investors

In 2019, cannabis producer Heritage Cannabis Holdings Corp. acquired a 30% stake in EndoDNA, indicating strategic interest in the company's innovative approach to personalized cannabinoid therapy.

Utilization of Capital

The capital raised has been utilized to develop and enhance EndoDNA's proprietary technologies, expand research collaborations, and support the commercialization of their personalized health solutions.

Pipeline Development

Key Pipeline Candidates

• EndoDNA Test Kit: A comprehensive DNA test analyzing over 500 genes and more than 550,000 single nucleotide polymorphisms to provide personalized health insights.

• Menopause Biotype Test: A genetic test developed in collaboration with Dr. Jennifer R. Berman to predict menopausal symptoms and inform personalized treatment plans.

Stages of Development

Both tests are in the commercialization phase, with the EndoDNA Test Kit launched in Canada in December 2019 and the Menopause Biotype Test introduced in July 2024.

Target Conditions

• EndoDNA Test Kit: Aims to personalize cannabinoid therapy for various health conditions by analyzing genetic predispositions.

• Menopause Biotype Test: Targets menopausal symptoms and associated health risks in women.

Anticipated Milestones

• EndoDNA Test Kit: Expansion into additional markets and integration with healthcare providers.

• Menopause Biotype Test: Further research collaborations and clinical studies to validate and refine the test.

Technological Platform and Innovation

Proprietary Technologies

• Endo·Decoded Report: Provides a detailed analysis of genetic variants related to cannabinoid metabolism and response.

• Endo·Aligned Formulations: Offers product recommendations tailored to individual genetic profiles.

Significant Scientific Methods

• Genomic Analysis: Utilizes comprehensive DNA testing to identify genetic variants affecting health and wellness.

• AI Integration: Employs machine learning algorithms to predict treatment efficacy and tailor wellness plans.

Leadership Team

Len May – Founder & CEO

With over 30 years of entrepreneurial experience, Len May has contributed to published peer-reviewed journal articles and clinical trials advancing the understanding of the endocannabinoid system and its impact on personalized health and wellness.

Eric Kaufman – Founder & COO

An entrepreneur and innovator with a background in product development, manufacturing, and technology, Eric Kaufman is the driving force behind the creation of EndoDNA's revolutionary endocannabinoid super-chip and algorithm.

Douglas Gintz – Chief Technology Officer

A veteran healthcare professional with over 30 years of experience, Douglas specializes in emerging technologies and has developed adaptive manufacturing compliance systems and native web applications for Fortune 500 companies and healthcare.

Amanda Vega – Chief Marketing Officer

With a strategic business and marketing background, Amanda has developed signature products and online marketing capabilities, contributing to the growth of various online marketing services.

Steve Sangapu – Director of Cloud Services

Steve orchestrates comprehensive cloud initiatives, from infrastructure modernization to custom development and AI/ML integration, driving the creation of robust, scalable, and innovative solutions across various cloud domains.

Tim Leslie – Strategic Advisor

A 20-year Amazon executive, Tim supported the launch of Amazon’s international retail businesses and operations and led the launch of Prime Video in over 200 countries and territories.

Clint Sharples – Board Member

CEO of Modu-Loc Fence Rentals and Chairman of Strategic Aviation and Sky Café, Clint brings extensive experience in business management and strategic growth.

Eben Britton – Advisory Board Member

Former NFL player and dedicated cannabis activist, Eben is now the host of the Mindful Warrior podcast, advocating for cannabis education and wellness.

Robert Griffith – Advisory Board Member

Former NFL Pro-Bowler and All-Pro, Robert played 13 NFL seasons with the Minnesota Vikings and is recognized for his contributions to sports and community engagement.

Dr. Allen Lawrence – Science Board Member

An expert in medical cannabis, Dr. Lawrence graduated from UC Irvine and completed gynecology training at Cedars Sinai Medical Center in Los Angeles.

Dr. Wellington Briques – Science Board Member

With a medical degree from the University of São Paulo and an MBA in Marketing, Dr. Briques has held significant roles in pharmaceuticals and biotech companies, focusing on patient care and medical education.

Dr. Jennifer R. Berman – Science Board Member

A urologist and women's health expert, Dr. Berman co-founded the Female Sexual Medicine Center and has pioneered research in female sexual health.

Competitor Profile

Market Insights and Dynamics

The precision medicine market, particularly in the realm of personalized cannabinoid therapy, is experiencing significant growth. Advances in genetic testing and AI are driving demand for personalized wellness solutions, with the global precision medicine market projected to reach USD 249.24 billion by 2030, growing at a compound annual growth rate (CAGR) of 16.3% from 2024 to 2030.